To access this element change to forms mode OFF
Grant Award View - GA58862
Preclinical development of lupidumab, a transforming new therapy for...
GA ID:
GA58862
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
1-Aug-2019
Publish Date:
30-Sep-2019
Category:
Medical Research
Grant Term:
1-Jan-2020 to 31-Dec-2022
Value (AUD):
$729,770.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 18/19 1.1 Health and Medical Research
Grant Program:
Development Grants
Grant Activity:
Preclinical development of lupidumab, a transforming new therapy for Chronic Lymphocytic Leukaemia
Purpose:
Chronic Lymphocytic Leukaemia (CLL) is a very common blood cancer. CLL cells actively shut down immune defenses in patients. Moreover, current and emerging more targeted therapies suppress immunity and over a quarter of patients will die from an infection, despite a good response to cancer treatments. Our laboratory has developed a new treatment for CLL which restores life-saving immunity in CLL. This proposal will allow us to demonstrate efficacy of this treatment prior to further development.
GO ID:
GO Title:
NHMRC Development Grants 2019 for funding in 2020
Internal Reference ID:
GNT1171598
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Melbourne
Recipient ABN:
84 002 705 224
Grant Recipient Location
Suburb:
Parkville
Town/City:
Parkville
Postcode:
3052
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
VIC
Postcode:
Country:
AUSTRALIA